AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AstraZeneca has completed a Phase IIa clinical study titled A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Pharmacodynamics of AZD4831 (Mitiperstat) in Participants With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) With Fibrosis. The study aimed to assess the safety and effectiveness of AZD4831 in treating NASH with fibrosis, a condition with significant unmet medical needs.
The study tested AZD4831, an experimental drug, against a placebo. AZD4831 is designed to treat non-cirrhotic NASH with fibrosis by potentially reducing liver inflammation and fibrosis.
This interventional study was randomized and triple-masked, involving parallel groups. Its primary purpose was treatment-focused, with participants and researchers unaware of who received the drug or placebo.
The study began on October 26, 2022, and completed its primary phase by March 24, 2025. The latest update was submitted on July 8, 2025. These dates are crucial for tracking the study’s progress and potential market entry of AZD4831.
The completion of this study could influence AstraZeneca’s stock performance positively, as successful results may enhance investor confidence and position the company favorably against competitors in the NASH treatment market.
The study is now completed, with further details available on the ClinicalTrials portal.